-
1.发明公开USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS 有权CK2抑制剂用于肿瘤的治疗和化学意识耐火AGAINST抗癌剂USE
公开(公告)号：EP1997506A1
公开(公告)日：2008-12-03
申请号：EP07711104.5
申请日：2007-02-28
发明人： PEREA RODRÍGUEZ, Silvio, Ernesto , PERERA NEGRÍN, Yasser , RODRÍGUEZ ULLOA, Arielis , GIL VALDÉS, Jeovanis , RAMOS GÓMEZ, Yassel , CASTELLANOS SERRA, Lila, Rosa , BETANCOURT NÚÑEZ, Lázaro, Hiram , SÁNCHEZ PUENTE, Aniel , FERNÁNDEZ DE COSSIO DORTA DUQUE, Jorge , ACEVEDO CASTRO, Boris, Ernesto , GONZÁLEZ LÓPEZ, Luis, Javier , BESADA PÉREZ, Vladimir , ALONSO, Daniel, Fernando , GOMEZ, Daniel, Eduardo
CPC分类号： A61K38/08 , A61K31/136 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/475 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.
摘要翻译： 本发明涉及一种药物组合确实包含一个酪蛋白激酶2（CK2）肽酶抑制剂（称为P15）地连同在癌症治疗和其中所用的标准的化疗药物一起施用，分离或顺序。 所述chemothearapeutic药物包括顺铂，紫杉酚，生物碱长春花从，5-氟尿嘧啶，阿霉素，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，易瑞沙和万珂（vortezomib）。 肽P15和抗癌药物之间的协同作用，以实现在组合所有这些是从10到每个细胞抑制药单独100倍低于每个细胞抑制药物的有效浓度。 在本发明中描述的药物组合显示较低的毒性相比，没有由防癌症治疗报告，因此，它darstellt一个关键优点为它在癌症治疗中的用途。 进一步，通过与肽P15预处理该药物组合的顺序给药导致耐火肿瘤的化疗增敏的抗癌治疗剂。
-
2.发明授权USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS 有权CK2抑制剂用于肿瘤的治疗和化学意识耐火AGAINST抗癌剂USE
公开(公告)号：EP1997506B8
公开(公告)日：2013-02-20
申请号：EP07711104.5
申请日：2007-02-28
发明人： PEREA RODRÍGUEZ, Silvio, Ernesto , PERERA NEGRÍN, Yasser , RODRÍGUEZ ULLOA, Arielis , GIL VALDÉS, Jeovanis , RAMOS GÓMEZ, Yassel , CASTELLANOS SERRA, Lila, Rosa , BETANCOURT NÚÑEZ, Lázaro, Hiram , SÁNCHEZ PUENTE, Aniel , FERNÁNDEZ DE COSSIO DORTA DUQUE, Jorge , ACEVEDO CASTRO, Boris, Ernesto , GONZÁLEZ LÓPEZ, Luis, Javier , BESADA PÉREZ, Vladimir , ALONSO, Daniel, Fernando , GOMEZ, Daniel, Eduardo
IPC分类号： A61K38/08 , A61K31/555 , A61K33/24 , A61K45/06 , A61P35/00
CPC分类号： A61K38/08 , A61K31/136 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/475 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
-
3.发明授权USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS 有权CK2抑制剂用于肿瘤的治疗和化学意识耐火AGAINST抗癌剂USE
公开(公告)号：EP1997506B1
公开(公告)日：2012-12-05
申请号：EP07711104.5
申请日：2007-02-28
发明人： PEREA RODRÍGUEZ, Silvio, Ernesto , PERERA NEGRÍN, Yasser , RODRÍGUEZ ULLOA, Arielis , GIL VALDÉS, Jeovanis , RAMOS GÓMEZ, Yassel , CASTELLANOS SERRA, Lila, Rosa , BETANCOURT NÚÑEZ, Lázaro, Hiram , SÁNCHEZ PUENTE, Aniel , FERNÁNDEZ DE COSSIO DORTA DUQUE, Jorge , ACEVEDO CASTRO, Boris, Ernesto , GONZÁLEZ LÓPEZ, Luis, Javier , BESADA PÉREZ, Vladimir , ALONSO, Daniel, Fernando , GOMEZ, Daniel, Eduardo
IPC分类号： A61K38/08 , A61K31/555 , A61K33/24 , A61K45/06 , A61P35/00
CPC分类号： A61K38/08 , A61K31/136 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/475 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
-
公开(公告)号：EP1992638A1
公开(公告)日：2008-11-19
申请号：EP07711100.3
申请日：2007-02-23
发明人： GUERRA VALLESPÍ, Maribel , TORRÉNS MADRAZO, Isis, del Carmen , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda, Elisa , GUILLÉN NIETO, Gerardo, Enrique , ACEVEDO CASTRO, Boris, Ernesto , UBIETA GÓMEZ, Raimundo
IPC分类号： C07K14/435 , A61K38/17
CPC分类号： C07K14/43509 , A61K38/00
摘要： The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKKYKGKFW, showing aminoacids substitutions, these peptides unable to bind to the lipopolysaccharide and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.
摘要翻译： 本发明涉及来自序列HYRIKPTFRRLKWKKYKGKFW的肽的开发，显示出氨基酸取代，这些肽不能结合脂多糖并具有抗肿瘤和免疫调节能力。 单独或组合使用这些肽可用于治疗癌症，并且与常规疗法协同作用。
-
公开(公告)号：EP1992638B1
公开(公告)日：2010-12-29
申请号：EP07711100.3
申请日：2007-02-23
发明人： GUERRA VALLESPÍ, Maribel , TORRÉNS MADRAZO, Isis, del Carmen , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda, Elisa , GUILLÉN NIETO, Gerardo, Enrique , ACEVEDO CASTRO, Boris, Ernesto , UBIETA GÓMEZ, Raimundo
IPC分类号： C07K14/435 , A61K38/17
CPC分类号： C07K14/43509 , A61K38/00
摘要： The invention relates to the development of peptides originating from sequence HYRIKPTFRRLKWKKYKGKFW, into which amino acid substitutions have been introduced, which guarantee the dissociation of the lipopolysaccharide-binding capacity and potentiate the anti-tumour and immunomodulatory effect. Said peptides and combinations thereof can be used in the treatment of cancer, as well as in synergism with other standard therapies.
-
-
-
-
搜索结果
5 条记录 (耗时 0.009 秒)
